Project Manager for TIDES and Small Molecules, Synthetic API MSAT
Descrizione del lavoro
Your impact begins here
As Project Manager for TIDES and Small Molecules in Synthetic API MSAT, you will support technology transfer and regulatory submission activities of chemically synthesised APIs. You will set direction and create clarity in a complex, regulated environment, keeping projects moving— so more people living with serious chronic diseases can access the treatments they need.
What you’ll bring
• A BSc, MSc or PhD in chemistry, chemical engineering or a related natural science, or equivalent experience.
• Experience in API manufacturing and in project management.
• The ability to engage stakeholders, align priorities and drive timelines and deliverables in a cross-functional setting.
• A structured, proactive approach and a quality mindset, with the ability to manage several projects at once and adapt quickly as things evolve.
- Strong collaboration and communication skills, with fluency in written and spoken English.
Useful, but not essential:
• Experience in CMC or MSAT, cGMP manufacturing, process validation, life-cycle management or regulatory documentation.
What you’ll do
You will represent and support the API track and coordinate the technical deliverables that keep synthetic API programmes on course.
In practice, you will:
- Drive priorities, timelines, deliverables, and alignment across the API sub-team
- Serve as cluster owner for the drug substance process cluster in regulatory filings
- Create clear project overviews and support subject matter experts in navigating complexity
- Represent the API track in CMC and life cycle management project core teams
- Communicate project status and align expectations with management, colleagues, and CDMOs
Who you’ll work with
You will join Synthetic API MSAT, a team of around 40 people in pharmaceutical manufacturing, based in Høje-Taastrup. The department connects CMC development with full-scale manufacturing and supports process implementation and optimisation with internal and external partners across Europe, North America and East Asia.
Your closest partners include colleagues across CMC, Regulatory Affairs, GCM, Quality, project offices, supply
and manufacturing, as well as CMO/CDMO partners. You will act as a clear point of entry for project interactions, bringing the right expertise together to move complex work forward at pace. On-site visits to manufacturing partners and some travel may be needed.
What you can expect here
You will work in an international, collaborative environment where your expertise is valued, and you are trusted to set direction and take ownership. The role offers the chance to build new skills across the value chain, grow through hands-on project work with internal and external partners, and make a visible impact on how synthetic APIs are developed and supplied.
Salary: For this role, the Annual Base Salary ranges from 742,600 DKK to 1,091,600 DKK (DK), corresponding to the level of the position. The placement within the salary range will be assessed during the recruitment process based on the candidate’s skills, competencies, knowledge, and relevant experience.
Incentives and
Benefits
The salary package may include short-term and/or long-term incentives as well as other employee benefits based on position level, location, functional area and relevant market benchmarks.
Learn more about our Reward Philosophy here.
Start now
Your impact begins today. If you are ready to bring clarity and momentum to synthetic API manufacturing, apply for the Project Manager for TIDES and Small Molecules role by 14th October. Applications are reviewed on an ongoing basis, so please apply as soon as possible.
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.
Competenze menzionate
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. Our story began over 100 years ago when two small Danish companies started producing the revolutionary new drug, insulin, which had just been discovered by Canadian scientists. These companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, were established by individuals driven by a common goal: to make life-saving insulin available to people with diabetes in Denmark and beyond. August Krogh, a Nobel laureate, and his wife Marie, a physician whose own diabetes fueled their quest, played a pivotal role in bringing insulin production to Denmark, leading to the founding of Nordisk Insulinlaboratorium in 1923. Shortly after, in 1925, the Pedersen brothers, former Nordisk employees, established Novo Terapeutisk Laboratorium, creating a dynamic of competition and innovation that would characterize the Danish pharmaceutical landscape for decades. After years of parallel growth and groundbreaking research, these two entities merged in 1989 to form Novo Nordisk A/S, a company that has since expanded rapidly. Today, we are a world leader not only in diabetes care but also in obesity care, haemophilia care, and therapies for rare endocrine disorders. Our commitment extends beyond developing innovative medicines; we strive to make them accessible to patients worldwide. We employ more than 77,000 people across 80 offices globally and market our products in approximately 170 countries. The Novo Nordisk Way, our set of guiding principles, is rooted in the vision of our founders and continues to inspire our thousands of colleagues. We are dedicated to applying our passion, skills, and commitment to defeat serious chronic diseases that affect hundreds of millions of people and represent some of the most urgent global health challenges. Our U.S. headquarters is located in Plainsboro, New Jersey, playing a vital role in the life sciences industry through sales, marketing, and clinical trial management for all Novo Nordisk U.S. products. We are also significantly investing in manufacturing capabilities, including a $4.1 billion expansion in North Carolina, to meet the growing demand for our diabetes and obesity medications.
Candidati per questo lavoro
Use the application link supplied with this listing to apply to Novo Nordisk. Check the destination before entering personal information.